(NASDAQ: ACHV) Achieve Life Sciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Achieve Life Sciences's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ACHV's revenue for 2026 to be $695,435,694, with the lowest ACHV revenue forecast at $693,701,440, and the highest ACHV revenue forecast at $697,169,947. On average, 2 Wall Street analysts forecast ACHV's revenue for 2027 to be $3,530,940,330, with the lowest ACHV revenue forecast at $3,468,507,200, and the highest ACHV revenue forecast at $3,593,373,459.
In 2028, ACHV is forecast to generate $8,324,417,280 in revenue, with the lowest revenue forecast at $8,324,417,280 and the highest revenue forecast at $8,324,417,280.